ECOG-ACRIN E4512 - A Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

https://clinicaltrials.gov/ct2/show/NCT02201992

ECOG ACRIN E4512
Cancer
Mehul Patel, MD
Enrolling
Lauren Jones, BS
(585) 747-4555